Chemomab Therapeutics Ltd Stock Price, News & Analysis

Chemomab (Nasdaq: CMMB) announced that co-founder and CEO Adi Mor, PhD will present at Oppenheimer’s Movers in Rare Disease Summit on December 11, 2025 in New York City.

The company will deliver a corporate overview at 2:15–2:45 pm EST at the Sofitel Hotel and will be available for one‑on‑one investor meetings with registered attendees. Investors should contact their Oppenheimer representative to register and schedule meetings.

Chemomab (Nasdaq: CMMB) reported Q3 2025 results and a corporate update on Nov 20, 2025. Management said FDA and EMA provided alignment that a single nebokitug Phase 3 registration trial using a composite clinical event endpoint could support approval, and Phase 3 design is near completion.

Data from the Phase 2 SPRING open-label extension up to 48 weeks showed favorable safety and consistent improvements in inflammatory and fibrotic biomarkers. Cash, cash equivalents and short-term deposits were $10.2M as of Sept 30, 2025, funding operations through end of Q4 2026.

Chemomab (Nasdaq: CMMB) announced that new clinical data from the Phase 2 SPRING trial of nebokitug in primary sclerosing cholangitis (PSC) will be presented at AASLD The Liver Meeting® on November 10, 2025. Open-label extension (up to 48 weeks) data show nebokitug was well tolerated with sustained or continued improvements in inflammatory and fibrosis biomarkers, including ELF score and liver stiffness, especially at 20 mg/kg. Mechanistic analyses report dose-dependent reductions in macrophage-related proteins, a dose-dependent increase in MST1, and correlations between MST1/CCL24 changes and liver stiffness. All three posters were designated Posters of Distinction.

Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.

CEO Dr. Adi Mor will deliver a prerecorded corporate presentation, which will be available from September 5, 2025, at 7:00 am ET for 90 days via webcast. The company's management team will also conduct one-on-one investor meetings on September 8-9, 2025.

Chemomab Therapeutics (Nasdaq: CMMB) reported Q2 2025 financial results and provided updates on its lead drug candidate nebokitug for Primary Sclerosing Cholangitis (PSC). The company is preparing for Phase 3 trials while pursuing strategic partnerships to optimize development resources. Key financial metrics include cash position of $9.5 million as of June 30, 2025, with runway through Q2 2026.

Notable developments include FDA alignment on CMC standards and toxicology testing requirements, new patent issuances in China and Russia, and multiple presentations of Phase 2 SPRING trial data at major scientific meetings. The company also announced plans to implement an ADS ratio change from 1:20 to 1:80 effective August 26, 2025, essentially functioning as a 1:4 reverse split for ADS holders.

Chemomab Therapeutics (Nasdaq: CMMB) presented positive Phase 2 SPRING trial data for nebokitug (CM-101) in primary sclerosing cholangitis (PSC) at BSG Live'25. The data was presented by Principal Investigator Dr. Douglas Thorburn at the British Society for Gastroenterology annual meeting in Glasgow.

The trial demonstrated that nebokitug was well-tolerated over 48 weeks of treatment, with a safety profile comparable to placebo during the initial 15-week double-blind portion. In patients with moderate to advanced disease, the drug showed dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects.

The open-label extension portion, lasting up to an additional 33 weeks, revealed sustained improvement in fibrosis markers and other PSC-related parameters. These positive results support advancement to Phase 3 trials, potentially positioning nebokitug as the first approved therapy for PSC.

Chemomab Therapeutics (NASDAQ: CMMB) has received positive feedback from two FDA meetings regarding the advancement of nebokitug to Phase 3 trials for Primary Sclerosing Cholangitis (PSC). The FDA agreed with Chemomab's Chemistry, Manufacturing, and Controls (CMC) strategy for late-stage development and commercialization. Additionally, in a Type C meeting, the FDA permitted non-clinical fetal and embryo developmental toxicology studies to be conducted parallel to Phase 3 trials, with results to be submitted as part of the Biologics Licensing Application (BLA). These regulatory milestones follow previous positive discussions about the Phase 3 pivotal trial design in December, as the company continues discussions with potential strategic partners.

Chemomab Therapeutics (NASDAQ: CMMB) has secured new patent protections in China and Russia for its lead product nebokitug (formerly CM-101), extending coverage up to 2041. The Chinese patent (No. ZL 2018 8 0018207.8) covers nebokitug's use in hepatic diseases, including primary sclerosing cholangitis (PSC), through 2038. The Russian patent (RU Patent 2022125176) protects various formulations and doses through 2041. These additions strengthen Chemomab's intellectual property portfolio for nebokitug, which has shown promising Phase 2 SPRING trial results in PSC treatment. The company has received FDA alignment on a regulatory approval pathway for PSC, a debilitating disease currently lacking effective treatments. Chemomab is pursuing potential partnerships to support a Phase 3 registrational trial in PSC.

Chemomab Therapeutics (NASDAQ: CMMB) reported significant progress in Q1 2025 with its lead drug candidate nebokitug for Primary Sclerosing Cholangitis (PSC). The company announced positive 48-week data from the SPRING trial, showing continued improvements in liver injury, inflammation, and fibrosis biomarkers. Notably, Chemomab aligned with FDA on a pathway to potential regulatory approval through a single, clinical-events-driven Phase 3 trial, positioning nebokitug to potentially become the first FDA-approved PSC treatment. Financial highlights include cash position of $10.6 million as of March 31, 2025, with runway extended to Q2 2026. R&D expenses decreased to $2.5 million from $3.1 million YoY, while net loss improved to $3.3 million from $3.9 million. The company is actively pursuing strategic partnerships to advance the Phase 3 program.